{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:11:20Z","timestamp":1758125480449},"reference-count":50,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.3892\/ijmm.2012.1221","type":"journal-article","created":{"date-parts":[[2012,12,21]],"date-time":"2012-12-21T13:32:33Z","timestamp":1356096753000},"page":"339-346","source":"Crossref","is-referenced-by-count":7,"title":["Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma"],"prefix":"10.3892","volume":"31","author":[{"given":"PAUL","family":"THELEN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LISA","family":"KRAHN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FELIX","family":"BREMMER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ARNE","family":"STRAUSS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RALPH","family":"BREHM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HAGEN","family":"LOERTZER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2012,12,21]]},"reference":[{"key":"key20180107233450_b1-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1007\/s00120-009-2076-3","article-title":"PSA - Quo vadis?","volume":"48","author":"B\u00f6rgermann","year":"2009","journal-title":"Urologe A"},{"key":"key20180107233450_b2-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"key20180107233450_b3-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1210\/me.2008-0017","article-title":"The contribution of different androgen receptor domains to receptor dimerization and signaling","volume":"22","author":"Centenera","year":"2008","journal-title":"Mol Endocrinol"},{"key":"key20180107233450_b4-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.tem.2010.01.002","article-title":"Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer","volume":"21","author":"Knudsen","year":"2010","journal-title":"Trends Endocrinol Metab"},{"key":"key20180107233450_b5-ijmm-31-02-0339","first-page":"62","article-title":"Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA","volume":"1","author":"Wang","year":"2009","journal-title":"Am J Transl Res"},{"key":"key20180107233450_b6-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.bjc.6604199","article-title":"Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy","volume":"98","author":"Weichert","year":"2008","journal-title":"Br J Cancer"},{"key":"key20180107233450_b7-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pros.20022","article-title":"Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer","volume":"59","author":"Halkidou","year":"2004","journal-title":"Prostate"},{"key":"key20180107233450_b8-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"key20180107233450_b9-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"G\u00f6ttlicher","year":"2001","journal-title":"EMBO J"},{"key":"key20180107233450_b10-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1158\/0008-5472.CAN-05-0487","article-title":"Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo","volume":"66","author":"Xia","year":"2006","journal-title":"Cancer Res"},{"key":"key20180107233450_b11-ijmm-31-02-0339","first-page":"25","article-title":"Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells","volume":"24","author":"Thelen","year":"2004","journal-title":"Int J Oncol"},{"key":"key20180107233450_b12-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1158\/1535-7163.MCT-07-0197","article-title":"The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment","volume":"6","author":"Stettner","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"key20180107233450_b13-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1756-8722-2-45","article-title":"Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy","volume":"2","author":"Yuan","year":"2009","journal-title":"J Hematol Oncol"},{"key":"key20180107233450_b14-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1126\/science.275.5308.1943","article-title":"PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer","volume":"275","author":"Li","year":"1997","journal-title":"Science"},{"key":"key20180107233450_b15-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ng0497-356","article-title":"Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers","volume":"15","author":"Steck","year":"1997","journal-title":"Nat Genet"},{"key":"key20180107233450_b16-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0065-230X(09)02002-8","article-title":"PI3K\/PTEN signaling in angiogenesis and tumorigenesis","volume":"102","author":"Jiang","year":"2009","journal-title":"Adv Cancer Res"},{"key":"key20180107233450_b17-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/pros.20410","article-title":"Expression of mTOR signaling pathway markers in prostate cancer progression","volume":"66","author":"Kremer","year":"2006","journal-title":"Prostate"},{"key":"key20180107233450_b18-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrc2536","article-title":"Insulin and insulin-like growth factor signalling in neoplasia","volume":"8","author":"Pollak","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"key20180107233450_b19-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.canlet.2011.04.004","article-title":"Insulin-like growth factor-binding protein-3 suppresses tumor growth via activation of caspase-dependent apoptosis and cross-talk with NF-\u03baB signaling","volume":"307","author":"Han","year":"2011","journal-title":"Cancer Lett"},{"key":"key20180107233450_b20-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1210\/jc.2002-020472","article-title":"Rapid insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 on endothelial cell survival","volume":"88","author":"Franklin","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"key20180107233450_b21-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/pros.10054","article-title":"Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model","volume":"50","author":"Igawa","year":"2002","journal-title":"Prostate"},{"key":"key20180107233450_b22-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20180107233450_b23-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.4049\/jimmunol.133.4.1710","article-title":"Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67","volume":"133","author":"Gerdes","year":"1984","journal-title":"J Immunol"},{"key":"key20180107233450_b24-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","article-title":"The Ki-67 protein: from the known and the unknown","volume":"182","author":"Scholzen","year":"2000","journal-title":"J Cell Physiol"},{"key":"key20180107233450_b25-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"31674","DOI":"10.1074\/jbc.M104309200","article-title":"The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth","volume":"276","author":"Yuan","year":"2001","journal-title":"J Biol Chem"},{"key":"key20180107233450_b26-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/med.10017","article-title":"Anti-tumor mechanisms of valproate: a novel role for an old drug","volume":"22","author":"Blaheta","year":"2002","journal-title":"Med Res Rev"},{"key":"key20180107233450_b27-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.febslet.2004.04.025","article-title":"Expression of estrogen receptor \u03b2 in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis","volume":"566","author":"Cheng","year":"2004","journal-title":"FEBS Lett"},{"key":"key20180107233450_b28-ijmm-31-02-0339","first-page":"5331","article-title":"Frequent loss of estrogen receptor-beta expression in prostate cancer","volume":"61","author":"Horvath","year":"2001","journal-title":"Cancer Res"},{"key":"key20180107233450_b29-ijmm-31-02-0339","first-page":"1919","article-title":"Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays","volume":"61","author":"Latil","year":"2001","journal-title":"Cancer Res"},{"key":"key20180107233450_b30-ijmm-31-02-0339","first-page":"2051","article-title":"Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues","volume":"86","author":"Pasquali","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"key20180107233450_b31-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0303-7207(01)00418-X","article-title":"Estrogen receptor beta expression in human prostate tissue","volume":"178","author":"Pasquali","year":"2001","journal-title":"Mol Cell Endocrinol"},{"key":"key20180107233450_b32-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.lfs.2010.12.017","article-title":"Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001","volume":"88","author":"Wedel","year":"2011","journal-title":"Life Sci"},{"key":"key20180107233450_b33-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"15969","DOI":"10.1073\/pnas.0604193103","article-title":"Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1","volume":"103","author":"Chen","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107233450_b34-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11523-010-0141-x","article-title":"Targeting mTOR in cancer: renal cell is just a beginning","volume":"5","author":"Azim","year":"2010","journal-title":"Target Oncol"},{"key":"key20180107233450_b35-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1158\/0008-5472.CAN-08-4385","article-title":"Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer","volume":"69","author":"Zhang","year":"2009","journal-title":"Cancer Res"},{"key":"key20180107233450_b36-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1158\/1078-0432.CCR-08-3007","article-title":"Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts","volume":"15","author":"Fung","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20180107233450_b37-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2010.11.019","article-title":"Prostate cancer detection: a view of the future","volume":"59","author":"Thompson","year":"2011","journal-title":"Eur Urol"},{"key":"key20180107233450_b38-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000066230","article-title":"The role of the IGF system in cancer: from basic to clinical studies and clinical applications","volume":"63","author":"Moschos","year":"2002","journal-title":"Oncology"},{"key":"key20180107233450_b39-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1210\/er.2008-0028","article-title":"Unraveling insulin-like growth factor binding protein-3 actions in human disease","volume":"30","author":"Jogie-Brahim","year":"2009","journal-title":"Endocr Rev"},{"key":"key20180107233450_b40-ijmm-31-02-0339","first-page":"723","article-title":"Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the \u03b1\u03bd\u03b23 integrin and PI3-K\/Akt signaling","volume":"28","author":"Marelli","year":"2006","journal-title":"Int J Oncol"},{"key":"key20180107233450_b41-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.1158\/0008-5472.CAN-04-0919","article-title":"Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic\/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors","volume":"64","author":"Goya","year":"2004","journal-title":"Cancer Res"},{"key":"key20180107233450_b42-ijmm-31-02-0339","first-page":"6841","article-title":"HER-2\/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway","volume":"60","author":"Wen","year":"2000","journal-title":"Cancer Res"},{"key":"key20180107233450_b43-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1042\/bj20020585","article-title":"Androgen receptor expression is regulated by the phosphoinositide 3-kinase\/Akt pathway in normal and tumoral epithelial cells","volume":"366","author":"Manin","year":"2002","journal-title":"Biochem J"},{"key":"key20180107233450_b44-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10552-011-9883-8","article-title":"Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer","volume":"23","author":"Rowlands","year":"2012","journal-title":"Cancer Causes Control"},{"key":"key20180107233450_b45-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/pros.20587","article-title":"Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo","volume":"67","author":"Shabbeer","year":"2007","journal-title":"Prostate"},{"key":"key20180107233450_b46-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/1756-9966-29-149","article-title":"Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line","volume":"29","author":"Yagi","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"key":"key20180107233450_b47-ijmm-31-02-0339","first-page":"85","article-title":"Valproic acid inhibits human hepatocellular cancer cells growth in vitro and in vivo","volume":"9","author":"Machado","year":"2011","journal-title":"J Exp Ther Oncol"},{"key":"key20180107233450_b48-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/pros.20752","article-title":"RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid","volume":"68","author":"Morgan","year":"2008","journal-title":"Prostate"},{"key":"key20180107233450_b49-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/sj.bjc.6605882","article-title":"Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR","volume":"103","author":"Schayowitz","year":"2010","journal-title":"Br J Cancer"},{"key":"key20180107233450_b50-ijmm-31-02-0339","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/j.1464-410X.2006.06198.x","article-title":"Interfering with cell-survival signalling as a treatment strategy for prostate cancer","volume":"97","author":"Corcoran","year":"2006","journal-title":"BJU Int"}],"container-title":["International Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijmm.2012.1221\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T02:15:47Z","timestamp":1687918547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijmm.2012.1221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,21]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,12,21]]},"published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.3892\/ijmm.2012.1221"],"URL":"https:\/\/doi.org\/10.3892\/ijmm.2012.1221","relation":{},"ISSN":["1107-3756","1791-244X"],"issn-type":[{"value":"1107-3756","type":"print"},{"value":"1791-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,21]]}}}